Advertisement
ADPT vs NTRA
Which Stock Would AI Choose? Adaptive Biotechnologies Corporation (ADPT) vs. Natera, Inc. (NTRA) Stock Comparison
Key Takeaways
- Adaptive Biotechnologies Corporation (ADPT) operates in immune medicine diagnostics and treatment, while Natera, Inc. (NTRA) focuses on genetic testing and minimal residual disease monitoring.
- Recent market activity shows NTRA exhibiting stronger momentum amid positive clinical data releases and regulatory developments.
- ADPT has maintained relatively steadier positioning in a volatile healthcare sector with limited major catalysts in recent weeks.
- Sector exposure for both centers on biotechnology and diagnostics, though NTRA benefits from broader oncology and transplant applications.
- Risk factors include clinical adoption timelines for both, with NTRA facing noted competitive pressures in molecular residual disease testing.
- Market sentiment appears more favorable toward NTRA based on recent performance and news flow compared to ADPT.
Introduction
This comparison examines Adaptive Biotechnologies Corporation (ADPT) and Natera, Inc. (NTRA), two companies in the biotechnology and diagnostics space. Investors and traders seeking exposure to healthcare innovation, particularly in immune and genetic testing technologies, may find this analysis relevant for assessing relative positioning. The review focuses on business models, recent performance trends, and observable market factors to highlight contrasts without favoring either stock. Such comparisons assist in evaluating trade-offs in growth drivers and sector dynamics within the current environment.
ADPT Overview and Recent Performance
Adaptive Biotechnologies Corporation (ADPT) develops an immune medicine platform for diagnosing and treating diseases, leveraging adaptive immune system biology. In recent market activity, the stock has shown measured movements amid broader healthcare sector fluctuations. Limited major catalysts have surfaced in recent weeks, contributing to a more stable but less dynamic price behavior relative to peers. Sentiment has been influenced by ongoing platform advancements and partnerships, though news flow remains moderate. The company’s focus on immune-driven diagnostics positions it for long-term applications in oncology and immunology, with performance reflecting steady interest rather than sharp shifts.
NTRA Overview and Recent Performance
Natera, Inc. (NTRA) specializes in genetic testing, including its Signatera minimal residual disease (MRD) test and Prospera portfolio for transplant monitoring. Recent market activity has featured notable gains, supported by clinical study publications and regulatory milestones such as expanded coverage and certifications. The stock has demonstrated upward momentum in recent weeks, driven by positive data on recurrence prediction and new approvals. Sentiment benefits from strong year-to-date performance and upcoming earnings visibility, though competitive developments in the MRD space have introduced some offsetting considerations. Overall, recent performance reflects heightened investor attention to oncology and transplant testing applications.
Trending AI Robots
Tickeron’s Trending AI Robots page curates a selection of AI trading bots designed for various market conditions. Tickeron maintains hundreds of AI Trading Bots that trade thousands of different tickers, yet only the strongest performers suited to prevailing environments earn placement in this section. The platform currently highlights its best 25 trending bots selected from a total of 351 AI robots. These bots encompass diverse trading styles, strategies, timeframes, performance metrics, and ticker sets, spanning technical and fundamental approaches across volatility levels. Readers interested in automated strategies can explore the full range directly via the linked resource.
Head-to-Head Comparison
Adaptive Biotechnologies Corporation (ADPT) emphasizes immune system profiling for diagnostics and therapeutics, contrasting with Natera, Inc. (NTRA)’s focus on cell-free DNA testing for oncology and transplant applications. Growth drivers differ, with ADPT centered on platform expansion and NTRA on clinical validation and reimbursement expansion. Recent momentum favors NTRA, which has recorded stronger gains amid favorable news, while ADPT has exhibited more contained movements. Risk factors include execution on clinical adoption for both, with NTRA additionally navigating competitive entries in molecular residual disease (MRD) monitoring. Sector exposure overlaps in healthcare diagnostics, yet NTRA’s broader portfolio introduces distinct reimbursement and regulatory sensitivities. Market sentiment currently tilts toward NTRA based on observable catalysts and performance consistency.
Tickeron AI Verdict
Based on observable factors such as trend consistency, recent catalysts, and relative positioning, Tickeron’s AI would currently assign a higher probability of favor to Natera, Inc. (NTRA) over Adaptive Biotechnologies Corporation (ADPT). NTRA’s stronger recent momentum and clinical developments provide clearer signals of positive trajectory compared to ADPT’s steadier but less event-driven profile. This assessment remains probabilistic and tied to prevailing data rather than forward guarantees.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADPT is a StrongBuy and NTRA is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ADPT’s FA Score shows that 0 FA rating(s) are green whileNTRA’s FA Score has 1 green FA rating(s).
- ADPT’s FA Score: 0 green, 5 red.
- NTRA’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ADPT’s TA Score shows that 4 TA indicator(s) are bullish while NTRA’s TA Score has 3 bullish TA indicator(s).
- ADPT’s TA Score: 4 bullish, 4 bearish.
- NTRA’s TA Score: 3 bullish, 5 bearish.
Price Growth
ADPT (@Medical Specialties) experienced а +2.64% price change this week, while NTRA (@Medical Specialties) price change was +15.07% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +0.62%. For the same industry, the average monthly price growth was +7.93%, and the average quarterly price growth was +24.12%.
Reported Earning Dates
ADPT is expected to report earnings on Nov 05, 2026.
NTRA is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Medical Specialties (+0.62% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| ADPT | NTRA | ADPT / NTRA | |
| Capitalization | 3.89B | 44.8B | 9% |
| EBITDA | -20.94M | -227.7M | 9% |
| Gain YTD | 55.480 | 37.920 | 146% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 295M | 2.5B | 12% |
| Total Cash | 218M | 1.09B | 20% |
| Total Debt | 77.6M | 240M | 32% |
ADPT | NTRA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 40 | 78 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 47 Fair valued | 49 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 22 | |
SMR RATING 1..100 | 98 | 96 | |
PRICE GROWTH RATING 1..100 | 35 | 36 | |
P/E GROWTH RATING 1..100 | 100 | 100 | |
SEASONALITY SCORE 1..100 | 37 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ADPT's Valuation (47) in the Hospital Or Nursing Management industry is in the same range as NTRA (49) in the Biotechnology industry. This means that ADPT’s stock grew similarly to NTRA’s over the last 12 months.
NTRA's Profit vs Risk Rating (22) in the Biotechnology industry is significantly better than the same rating for ADPT (100) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew significantly faster than ADPT’s over the last 12 months.
NTRA's SMR Rating (96) in the Biotechnology industry is in the same range as ADPT (98) in the Hospital Or Nursing Management industry. This means that NTRA’s stock grew similarly to ADPT’s over the last 12 months.
ADPT's Price Growth Rating (35) in the Hospital Or Nursing Management industry is in the same range as NTRA (36) in the Biotechnology industry. This means that ADPT’s stock grew similarly to NTRA’s over the last 12 months.
ADPT's P/E Growth Rating (100) in the Hospital Or Nursing Management industry is in the same range as NTRA (100) in the Biotechnology industry. This means that ADPT’s stock grew similarly to NTRA’s over the last 12 months.
| ADPT | NTRA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 83% | 2 days ago 61% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| Momentum ODDS (%) | 2 days ago 87% | 2 days ago 82% |
| MACD ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 81% |
| Advances ODDS (%) | 9 days ago 83% | 10 days ago 80% |
| Declines ODDS (%) | 2 days ago 85% | 3 days ago 77% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 71% |
| Aroon ODDS (%) | 2 days ago 86% | 2 days ago 80% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PTF | 110.16 | 4.36 | +4.12% |
| Invesco Dorsey Wright Technology MomtETF | |||
| MQQQ | 232.86 | 3.15 | +1.37% |
| Tradr 2X Long Innovation 100 Monthly ETF | |||
| ZHOG | 51.12 | 0.06 | +0.11% |
| F/m Opportunistic Income ETF | |||
| JMTG | 50.07 | 0.01 | +0.02% |
| JPMorgan Mortgage-Backed Securities ETF | |||
| IBGL | 22.84 | -0.02 | -0.10% |
| iShares iBonds Dec 2055 Term Trsy ETF | |||
ADPT and
Correlation & Price change
A.I.dvisor indicates that over the last year, ADPT has been loosely correlated with AXON. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADPT jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To ADPT | 1D Price Change % | ||
|---|---|---|---|---|
| ADPT | 100% | -0.55% | ||
| AXON - ADPT | 56% Loosely correlated | -5.74% | ||
| VCYT - ADPT | 53% Loosely correlated | -3.73% | ||
| PSNL - ADPT | 51% Loosely correlated | +1.36% | ||
| ARRY - ADPT | 50% Loosely correlated | -2.99% | ||
| NTRA - ADPT | 49% Loosely correlated | +1.04% | ||
More | ||||
NTRA and
Correlation & Price change
A.I.dvisor indicates that over the last year, NTRA has been loosely correlated with ISRG. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if NTRA jumps, then ISRG could also see price increases.
| Ticker / NAME | Correlation To NTRA | 1D Price Change % | ||
|---|---|---|---|---|
| NTRA | 100% | +1.04% | ||
| ISRG - NTRA | 53% Loosely correlated | +0.01% | ||
| GH - NTRA | 50% Loosely correlated | +0.01% | ||
| ADPT - NTRA | 50% Loosely correlated | -0.55% | ||
| MTD - NTRA | 47% Loosely correlated | +0.09% | ||
| GKOS - NTRA | 47% Loosely correlated | +2.54% | ||
More | ||||